Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-05-05 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
Regulatory Filings Classification · 95% confidence The document is a press release dated May 5, 2025, announcing that GENFIT will present research updates, including six posters, at the EASL Congress 2025 regarding Acute-on-Chronic Liver Failure (ACLF). It details the specific posters, scheduled events (EASL Studio, EF CLIF co-organization, Advisory Board meetings, Investigator Meeting), and provides background information on EASL, ACLF, and GENFIT. This is a proactive announcement detailing planned participation and presentation of scientific data at a major industry conference, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It functions as an Investor Presentation (IP) of upcoming scientific milestones or a general announcement about scientific progress, but given the context of presenting research posters and participating in scientific sessions, 'Investor Presentation' (IP) is the most fitting category for communicating forward-looking scientific and pipeline updates to investors and the public. It is not a short announcement linking to a full report, so RPA/RNS is less appropriate than IP.
2025-05-05 French
GENFIT to Present Latest ACLF Research at EASL Congress 2025
Regulatory Filings Classification · 98% confidence The document is a press release dated May 5, 2025, announcing that GENFIT will present research at the EASL Congress 2025. It details the specific posters (Poster #1 through #6) that will be presented, covering research on ACLF and MASH. It also describes several associated events like an EASL Studio session, an Advisory Board meeting, and an Investigator Meeting. This content is a high-level announcement about participation in a scientific conference and the data being presented, rather than the full financial report (10-K), a quarterly report (IR), or a formal earnings release (ER). It is an announcement intended for investors and the scientific community regarding research dissemination. Since it is an announcement about company activities and research updates, and not a formal regulatory filing like a 10-K or a specific financial report, it fits best under the general category of Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on presenting research findings and pipeline updates to the investment community via a press release format, 'Investor Presentation' (IP) is the most appropriate fit, as it often accompanies or precedes detailed presentations, even if this specific document is the announcement itself. However, since the document is primarily an announcement of participation and presentation of scientific data, and not the presentation slides themselves, it functions as a general corporate update. Comparing the options, it is not a formal financial report, nor a management discussion, nor a proxy statement. It is an announcement of scientific/research progress. In the context of financial databases, announcements detailing research progress and conference participation are often categorized under Investor Presentation (IP) or sometimes Regulatory Filings (RNS). Given the detailed breakdown of poster titles and associated events, it serves an investor relations function by highlighting R&D progress. I will classify it as Investor Presentation (IP).
2025-05-05 English
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du Rapport Annuel Form 20-F 2024
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary purpose is to announce that the company has filed its 'Document d'Enregistrement Universel 2024' (Universal Registration Document 2024) with the AMF and its 'Rapport Annuel Form 20-F 2024' (Annual Report Form 20-F 2024) with the SEC. Although it mentions the contents of these annual reports (financial report, management report, governance report), the document itself is the announcement of their publication/filing, not the full reports themselves. According to Rule 2, when a document is short and announces that a report has been published or filed, it should be classified as a Report Publication Announcement (RPA). The Form 20-F is the US equivalent of a 10-K, but this text is the announcement, not the 20-F itself.
2025-04-29 French
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
Report Publication Announcement Classification · 100% confidence The document is explicitly titled a "PRESS RELEASE" and its primary purpose is to announce that GENFIT has filed two major annual reports: the "2024 Universal Registration Document" with the AMF and the "2024 Annual Report on Form 20-F" with the SEC. The text details what is included in these reports (financial report, management report, governance report, etc.) but does not contain the full content of those reports. According to Rule 2, when a document is short and announces the publication or filing of a full report (like a 20-F or Universal Registration Document), it should be classified as a Report Publication Announcement (RPA). The Form 20-F is the US equivalent of a 10-K, but since this document is merely announcing its filing, RPA is the correct classification based on the provided definitions and rules.
2025-04-29 English
Document d'Enregistrement Universel 2024
Annual Report Classification · 100% confidence The document is titled 'DOCUMENT D’ENREGISTREMENT UNIVERSEL 2024' and includes the 'Rapport Financier Annuel' (Annual Financial Report). It is a comprehensive report covering the company's activities, governance, risk factors, financial statements, capital and shareholding, and extra-financial performance. The document references the filing with the AMF (French financial regulator) under EU regulation 2017/1129, which governs universal registration documents used for public offerings and market admissions. The content includes detailed financial data, consolidated accounts, governance, risk management, and ESG information, typical of a full annual report. The length is substantial (15,000 characters), indicating it is the full report, not just an announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-29 French
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) multiple times and announces upcoming data presentation at a scientific congress (EASL 2025) regarding clinical trial results (Phase 2 for elafibranor in PSC). It also includes standard sections like 'A PROPOS DE GENFIT' and 'AVERTISSEMENT' (Forward-Looking Statements), which are characteristic of corporate news releases intended for broad distribution, including investors and the media. Since it is an announcement about data presentation and not the full financial report (10-K, IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice, the most appropriate classification is a general Regulatory Filing (RNS) or, given its nature as a corporate announcement, it could also be considered a type of Investor Presentation material if it were a slide deck, but as a press release announcing results/events, RNS is the best fit among the provided options, as it is a general regulatory/corporate announcement.
2025-04-28 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.